Encontrados 2 documentos, a visualizar página 1 de 1
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y.; Coelho, T.; Berk, J.; Cruz, M.; Ericzon, B.; Ikeda, S.; Lewis, W.; Obici, L.; Planté-Bordeneuve, V.; Rapezzi, C.; Said, G.; Salvi, F.Transthyretin amyloidosis is a progressive and eventually fatal disease primarily characterized by sensory, motor, and autonomic neuropathy and/or cardiomyopathy. Given its phenotypic unpredictability and variability, transthyretin amyloidosis can be difficult to recognize and manage. Misdiagnosis is common, and patients may wait several years before accurate diagnosis, risking additional significant irreversib...
Long-term effects of tafamidis for the treatment of transthyretin familial amyl...
Coelho, T.; Maia, L.; Martins-Silva, A.; Cruz, M.; Planté-Bordeneuve, V.; Suhr, O.; Conceição, I.; Schmidt, H.; Trigo, P.; Kelly, J.; Labaudinière, R.Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005). This 12-month, open-label extension study evaluated the long-term safety, tolerability, and efficacy of tafamidis 20 mg once daily in 86 patients who earlier received blinded treatment with tafamidi...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||